Fasenra Approved for New Use in India

  Published 1 year ago

AstraZeneca’s Fasenra (Benralizumab) has received Indian regulatory approval for an additional indication: treating adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Marketing is pending further statutory approvals.

  • Fasenra gets expanded use in India.
  • Treats EGPA in adult patients.
  • Approval from Indian regulators.

You might like these

Volvo Cars Announces 3,000 Job Cuts

Landmark Cars Expands in Hyderabad

RBI Report: Currency & Reserve Money Update

Why Rupee Lags Asian Currencies in Weak Dollar

Adani Group Stocks Fall Amid US Probe

Reliance & Bhutan: 500MW Solar Power Deal

India Growth Outlook & Viksit Bharat

News that matters the most ⚡